MoonLake's Drug Aced Its Biggest Test. Wall Street Shrugged.

Analyst consensus heading into the readout was already lukewarm. Marketbeat data around this period showed 10 Buy ratings, 4 Holds, and 3 Sells, with a consensus price target of $24.57. The gap between those numbers and the stock price tells you that some analysts see big upside, while others are deeply skeptical.

And that skepticism has a history.

MoonLake's Transparency Problem

This isn't the first time MoonLake has released strong-looking numbers only to face pushback about how those numbers were presented. The company's disclosures have drawn criticism for being difficult to evaluate, even as MoonLake framed results positively.

To be clear: there's no evidence of fraud or data manipulation here. No SEC enforcement actions, no smoking guns. The criticism is about presentation and selectivity, not fabrication. But in biotech, perception matters almost as much as p-values. When a company develops a reputation for making data hard to parse, every new readout gets scrutinized through that lens.

It's the "boy who cried wolf" effect, except the boy might actually be telling the truth. The problem is that fewer people stop to listen.

The Nanobody Angle

Sonelokimab isn't just another antibody drug. It's a nanobody, a much smaller molecule (roughly 40 kilodaltons, compared to the ~150 kDa of a standard antibody). Think of the difference between sending a delivery truck versus a motorcycle courier through city traffic; the smaller vehicle can navigate tighter spaces and reach destinations the truck can't.

The drug targets both IL-17A and IL-17F, two inflammatory proteins that drive diseases like psoriatic arthritis. Older drugs in this space, like Novartis's secukinumab, only block IL-17A. Newer competitors like UCB's bimekizumab block both, but sonelokimab's nanobody format adds a twist: an albumin-binding domain that's designed to concentrate the drug at inflamed sites, where albumin (a blood protein) tends to accumulate.

Whether that translates into meaningful clinical advantages over bimekizumab is still an open question. The IZAR-1 data look competitive, but head-to-head trials are the only real way to settle the debate.

The Bigger Picture: Filing Season Approaches

MoonLake isn't just running one program. The company plans to submit a BLA (Biologics License Application) for sonelokimab in hidradenitis suppurativa by the end of September 2026, with FDA acceptance and potential Priority Review notification expected by November. If everything goes smoothly, a U.S. launch could happen in the second half of 2027.

The HS data supporting that filing have been building over multiple readouts. In the VELA trials, 67.2% of patients achieved HiSCR75 (a 75% improvement in inflammatory lesion counts) at Week 52, while 33.1% hit HiSCR100, essentially complete clearance. Those response rates deepened over time, climbing from Week 40 to Week 52, which is exactly what you want to see in a chronic disease.

Meanwhile, MoonLake has a second psoriatic arthritis trial, IZAR-2, with results expected in Q4 2026. That readout will be crucial: it either confirms the IZAR-1 signal or raises new questions.

What to Watch

MoonLake is sitting at an awkward crossroads. The science looks promising. The pipeline is advancing on multiple fronts. A regulatory filing is weeks away. But the company carries baggage around how it communicates data, and the stock reflects that trust deficit.

For investors, the next few months are a gauntlet of catalysts: the HS filing in September, FDA feedback in November, IZAR-2 data in Q4, and full IZAR-1 results in early 2027. Each one is a chance to either rebuild credibility or deepen the skepticism.

Sonelokimab's clinical results keep checking boxes. The question MoonLake still needs to answer isn't whether the drug works. It's whether the company can convince a skeptical audience to believe what they're seeing.

Sandoz Is Buying Its Biosimilar Future From China

Sandoz just committed up to $322 million to license biosimilars from a Chinese company most people have never heard of. The deal with Shanghai Henlius signals something bigger: China's biologics ecosystem has gone from follower to supplier for the world's largest biosimilar company.